NSEOutcome of Board Meeting1 Nov 2026 · 1 Nov 2026, 03:09 pm

Outcome of Board Meeting

Sai Parenterals Limited · SAIPARENT

✦ AI SummaryResults

Sai Parenterals Limited has submitted its financial results for the quarter and half year ended September 30, 2026, and has also approved the acquisition of the remaining 25% equity shareholding in its subsidiary SP Analytics Private Limited, making it a wholly owned subsidiary.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Attachments (1)

📄

SAIPARENTERALS_01112026150410_OutcomeOfTheBoarMeetingSigned.pdf

pdf

Download →
View document text
SATI PARENTERALS Date: 01° November, 2026 The Manager The Manager BSE Limited NSE Limited P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SATPARENT) Unit: Sai Parenteral’s Limited Sub: Outcome of Board Meeting held on Sunday, 01t November, 2026. With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenteral’s Limited held on Sunday, the 01* day of November, 2026 at 12:30 p.m. at the Registered Office of the Company considered and approved the following: 1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. 2. Limited Review Reports (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. 3. Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary of the Company in which the company holds 75%, thereby making it a wholly owned subsidiary of the Company. (Details are attached as Annexure A) 4. Constitution of Management Committee for smooth functioning and administration convenience of the Company. (Details are attached as Annexure B) 5. Pursuant to the approval of the Board of Directors of the Company at its meeting held on August 11, 2026, the Company has completed the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited. Consequent to the aforesaid acquisition, Saicriti Pharma Private Limited has become a subsidiary of the Company with effect from the date of completion of the acquisition. SAIPARENTERALS www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. frvrmmemmesepsemt mail: infoasaiparontorals.co©m 1917997991306 Email: infoasai toral + SATI PARENTERALS The Meeting concluded at 2:30 p.m. This is for the information and records oft he Exchanges, please. Thanking you. Yours sincerely, For Sai Parenterals Limited Anil Kumar Karusala Managing Director (DIN- 01866646) SAIPARENTERALS www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. frvrmmemmespey mail: infoasaiparontorals.co©m 1917997991306 Email: infoasai toral + SATI PARENTERALS Annexure — A [Details _under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025- CFD-POD2/1/3762/2026 dated January 30, 2026] Name of the Target Ms. SP Analytics Private Limited Entity Details in brief such Nil as size, turnover etc ‘Whether the The acquisition falls within the ambit of Related Party Transactions (RPTs) acquisition would under the applicable provisions of the Companies Act, 2013 and SEBI fall within related (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the party transaction(s) entity being acquired is a related party of the Company. Further, the and whether the Promoter(s)/Promoter Group have an interest in the entity being acquired by promoter/promoter virtue of their relationship with the said entity. group/ group companies have any The transaction is proposed to be undertaken at arm’s length, based on the interest in the entity terms and conditions mutually agreed upon by the parties and duly supported being acquired? If by an appropriate assessment, wherever applicable. yes, nature of interest and details thereof and whether the same is done at “arm’s length” Industry to which Pharma Sector the entity being acquired belongs Objects and impact Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics of acquisition Private Limited, a subsidiary of the Company in which the company holds (including but not 75%, thereby making it a wholly owned subsidiary of the Company. limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) Brief Details of any Not required governmental or regulatory approvals required for the acquisition Indicative Time | On or before 31.12.2026 period for completion of the acquisition SAIPARENTERALS wwiw.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032 Email: infosaiparontorals.com (© 1917997991206 CIN:U24231762001PLCO36043 SATI PARENTERALS Consideration - Cash whether cash consideration or share swap or any other form and details of the same Cost of acquisition Acquisition of 2,500 equity shares of face value Rs.10/- each, aggregating to and/or the price at Rs.25,000/-. which the shares are acquired Percentage of | Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics shareholding /| Private Limited, a subsidiary of the Company in which the company holds control acquired | 75%, thereby making it a wholly owned subsidiary of the Company. and / or number of shares acquired Brief background M/s. S P Analytics Private Limited was incorporated on November 16, 2023, about the entity with the main object of undertaking testing, analysis and examination of acquired in terms of pharmaceuticals, medicines, drugs and other related materials. The Company products/line of has reported nil turnover during the last three financial years. business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); SAIPARENTERALS wwiw.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. Email: infoasaiparontorals.com (© 1917997991306 CIN:U24231762001PLCO36043 SATI PARENTERALS Annexure — B MANAGEMENT COMMITTEE S.No Name Designation Category 1. Anil Kumar Karusala Managing Director Chairman 2. Vijitha Gorrepati ‘Whole Time Director | Member 3. Kunal Kakumanu Executive Director Member 4. Arvind Gannimitta Chief Operating Officer | Member 5. Ashwani Singh Bisht Company Secretary & | Member Compliance Officer SAIPARENTERALS www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. frvrmmemmespey mail: infoasaiparontorals.co©m 1917997991306 Email: infoasai toral + SAI PARENTERAL'S LIMITED Regd. Off.; Plot No 39, 5th Floor Lavanya Arcade. Jayabheri Enclave, Gachibowii, Seri Lingampally, Telangana, India - 600032 CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301 Unaudited Consolidated Financial Results For The Quarter And Half Year Ended On 30th September, 2026 (<in Millions) warter Ended Half Yearndeg inancial Year 3 Particulars ¢ Ended No. 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026 Unaudited |Unaudited _|Unaudited _[Unaudited | Audited | _Audited 1 |income 2. Revenue from Operations 194018| 178672 53528 373590 86918 | 3,80998 b. Other income 3719 3741 1335 7460 25.09 85.20 Total income 198637 182013 54863 | 3,81050] 894.27]| 38918 W [Expenses 2. Cost of materials consumed 82244 | 116123 20038 | 19m366| es226| 238112 b. Purchases of stock in trade - <. Change in inventories of finished goods, workn-progress and stoc) 207.63 (98.97) (52:86) 10866 (86.12) an d. Employees benefits expense 12855 15.42 399 24397 6853 29281 e. Finance costs 8982 93.60 2167 183.42 4631 184.38 . Depreciation and amartisation expense 25090 8110 14.36 33200 2885 16852 /& Other Expenses 38814 37386 3755 762.00 7285 707.96 Total Expenses 188708 172623 a57.09 | 3,61371| 78268 3,750 10 {Profit/(Loss) before Exceptional Items & Tax (1) 9889 97.90 o154 19%.79 mss| 1928 IV |Exceptional Items (Refer Note No.3) - vV [Profit/{Loss) before Tax (1) 98.89 9750 91.54 19679 11159 11928 VI [Tax expense: Current tax 1615 an 2804 5786 3154 4934 Deferred tax (22.36) (23.05) (#s.41) 240 (72565) Earlier Years - - - Vil Profit/{Loss) after [Showing first 8,000 characters — download PDF for full document]